Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

OBJECTIVE: To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Pharmacoeconomics
Huvudupphovsmän: Emery, Paul, Van Keep, Marjolijn, Beard, Steve, Graham, Chris, Miles, LaStella, Jugl, Steffen Marc, Gunda, Praveen, Halliday, Anna, Marzo-Ortega, Helena
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer International Publishing 2018
Ämnen:
Original Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021464/
https://ncbi.nlm.nih.gov/pubmed/29797186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-018-0675-9
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk